Rapport Therapeutics, Inc. Common Stock (RAPP NASDAQ) stock market data APIs
$47.3545
1.45(3.1%)
as of August 12, 2026
Try our APIs with
free plan!
Rapport Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Prev. Close
47.3545
Open
48.8072
High
49.0541
Low
46.8947
52 wk Range
13.86-49.5
Market Cap
2 290 M
Shares Outstanding
47 978 K
Revenue
20 000 K
EPS
-1.19
Beta
0.971
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Rapport Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at €19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
Get Rapport Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Rapport Therapeutics, Inc. Common Stock Fundamental Data
Rapport Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue: 20 000 K
- EBITDA: -152 556 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
€
59.99
/mo.
End-of-day & Earnings data
Get Rapport Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
€
19.99
/mo.
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.93
Get Rapport Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
€
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Rapport Therapeutics, Inc. Common Stock News
New
Rapport Therapeutics reports Q2 results
* Rapport Therapeutics press release [https://seekingalpha.com/pr/20607480-rapport-therapeutics-reports-second-quarter-2026-financials-and-provides-business-update] (RAPP [https://seekingalpha.com/s...
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
Key Points COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41.58 per share. This sale represented 6.2% of Gault's dir...
Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?
Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro's Substack. In this article, we will summarize the bulls' thesis on RAPP. Rapport Therapeutics,...
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?
In late May 2026, analysts BTIG and Truist highlighted Rapport Therapeutics’ RAP-219 program after the company reported progress toward Phase 3 trials, supported by earlier Phase 2a follow-up data. ...
Get Rapport Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
€19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
€99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
